Postoperative nausea and vomiting
Conditions
Interventions
Oliceridine Group (Group O ):Oliceridine 30mg + 0.9% Sodium Chloride Solution.
Sufentanil Group (S Group):Sufentanil 75µg + 0.9% Sodium Chloride Solution.
Sponsors
Guangzhou First People‘s Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18-65 who are scheduled to undergo gynecological laparoscopic surgery under general anesthesia; 2. ASA ?—?; 3. Expected to require opioid analgesia for patient-controlled intravenous analgesia.
Exclusion criteria
Exclusion criteria: 1. BMI >= 28 kg/?; 2. Severe hepatic and renal dysfunction; 3. Refusal or inability to provide a valid informed consent form for other reasons; 4. Patients with a history of opioid allergy or contraindications to oliceridine or sufentanil; 5. Those who have a history of chronic pain, alcohol or drug abuse; 6. Those who have previously participated in clinical studies related to oliceridine or have participated in other drug studies within the past three months; 7. Expected postoperative need for mechanical ventilation or ICU admission; 8. Patients with mental disorders, communication difficulties and other difficulties to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of nausea and vomiting during the PACU stay and within 24 hours after after discharge.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative consumption of PCA;NRS pain score;Quality of Recovery Score QoR-15;Number of rescue antiemetics or additional analgesics.;The occurrence of other opioid-related adverse events (ORAEs); | — |
Countries
China
Contacts
Public ContactZheng Bin
Guangzhou First People‘s Hospital
Outcome results
None listed